Clinical Evaluation of Systemic Inflammation Markers in Patients Diagnosed with Pulmonary Tuberculosis
Bozok Tıp Dergisi · 15.03.2026 · 16 (1) · 37-47
DOI: 10.16919/bozoktip.1834930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bozok Tıp Dergisi, online erschienen am 15.03.2026. Verfasst von Ümmühan Tuğba Tümüklü und 5 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Objective
This study aimed to investigate the levels of systemic inflammation markers—including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), hematological ratios, and complete blood count parameters—in individuals diagnosed with pulmonary tuberculosis (TBC). The clinical significance of these biomarkers in the diagnosis, disease activity, and treatment response was evaluated, and their associations with age, sex, and comorbidities were also analyzed.Materials and Methods: Following ethics approval (2025-GOKAEK-2517), hospital records of patients aged 18–80 years diagnosed with pulmonary tuberculosis between 2023 and 2025 at Yozgat Bozok University and Sivas Cumhuriyet University were retrospectively reviewed. The control group consisted of healthy individuals who presented during the same period. Hemogram parameters, CRP, ESR, and the Systemic Immune-Inflammation Index (SII) were assessed, and statistical analyses were performed using SPSS v22.0.
Results
A total of 134 individuals (67 TBC and 67 controls) were included. In the TBC group, 70.1% were male, and the mean age was 48.76 ± 18.01 years. Comorbidities were present in 70.1% of patients, most commonly COPD, hypertension, and coronary artery disease. The TBC group demonstrated significantly higher leukocyte, neutrophil, monocyte, platelet, CRP, ESR, and SII levels, while hemoglobin and lymphocyte levels were significantly lower (all p < 0.0001). Although the mean SII value was elevated (2772.51 ± 4004.20), it did not show a significant association with diagnostic test results or clinical outcomes.
Conclusion
The markedly elevated SII levels in patients with pulmonary tuberculosis suggest that this index may serve as a potential biomarker reflecting increased systemic inflammation. However, its limited correlation with diagnostic and clinical endpoints indicates that it should be considered a supportive—not standalone—parameter in clinical evaluation.
Förderung
- None
Zitieren
APA
Tümüklü, Ü. T., Taştemur, Ş., Üstündağ, M., Felek, D., Doğan, Ö. T., & Seyfikli, Z. (2026). Clinical Evaluation of Systemic Inflammation Markers in Patients Diagnosed with Pulmonary Tuberculosis. Bozok Tıp Dergisi, 16(1), 37-47. https://doi.org/10.16919/bozoktip.1834930
Vancouver
Tümüklü ÜT, Taştemur Ş, Üstündağ M, Felek D, Doğan ÖT, Seyfikli Z. Clinical Evaluation of Systemic Inflammation Markers in Patients Diagnosed with Pulmonary Tuberculosis. Bozok Tıp Dergisi. 2026;16(1):37-47. doi:10.16919/bozoktip.1834930
BibTeX
@article{Tmkl2026,
author = {Tümüklü, Ümmühan Tuğba and Taştemur, Şeyma and Üstündağ, Mert and Felek, Duygu and Doğan, Ömer Tamer and Seyfikli, Zehra},
title = {Clinical Evaluation of Systemic Inflammation Markers in Patients Diagnosed with Pulmonary Tuberculosis},
journal = {Bozok Tıp Dergisi},
year = {2026},
volume = {16},
number = {1},
pages = {37--47},
doi = {10.16919/bozoktip.1834930}
}
EUVIMED